Short description
Tolerx develops novel therapies that modulate T-cell activities to treat patients with autoimmune diseases, diabetes and cancer.
Description
Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.
Total funding
$$121212
Sign in for full access
Location
Cambridge, Massachusetts, United States, North America
Founded on
January 1, 2000
Non-profit?
No
Acquired?
No
Employees count
51-100
Investors
Absolutely Noaccess, Blurry Noaccess, No Way, Blurry Noaccess, Noway Youcantaccess, Blurry Noaccess, Noaccessforu, Blurry Noaccess, Uh Ohhhh, Noway Youcantaccess, Uh Ohhhh, No Way, Nopepepe
Sign in for full access
Founders
Douglas J. Ringler